Navigation Links
Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
Date:12/20/2007

New Board Member Brings Life Sciences Tools Experience to the Leader in

Cellular Bioenergetic Profiling

N. BILLERICA, Mass., Aug. 10 /PRNewswire/ -- Seahorse Bioscience, the leading provider of tools for real-time measurement of cellular bioenergetics in microplates, announced today that former Molecular Devices executive Joseph Keegan has been appointed to the company's Board of Directors. In this position, Keegan will apply his successful business experience in the life sciences industry to accelerate the growth of Seahorse Bioscience's novel technology for profiling cell metabolism.

"As the company moves into its next phase of growth, it will require a strong understanding of this market," said Jay Teich, Seahorse Bioscience's CEO. "Joe's tremendous success in building Molecular Devices, combined with his extensive labware experience makes him an ideal addition to our Board."

Keegan brings more than 25 years of experience managing life science tools businesses. As CEO of Molecular Devices, he developed a strategy combining internal growth with acquisitions to build the dominant supplier of detection solutions for drug discovery, clinical and research applications. Keegan joined MDC from Becton Dickinson and Company where he served as President of Worldwide Tissue Culture. Prior to Becton Dickinson, Keegan was Vice President of Microscopy and Scientific Instruments Division of Leica, Inc.

"Seahorse has developed a 'stethoscope for living cells.' The ability to measure cell metabolism in a truly non-invasive way has very broad applications," said Keegan. "Drawing on my experience with both instrument and labware businesses, I look forward to helping Seahorse grow a successful business in a field that I understand very well."

About Seahorse Bioscience

Seahorse Bioscience is changing cancer, obesity and diabetes drug discovery programs the world over. Seahorse headquarters are located in North Billeric
'/>"/>

SOURCE Seahorse Bioscience
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... World,s Top Gene Synthesis...rtium (IGSC) to Coordinate Best Practices in Risk ...rcent of Worldwide Gene Synthesis Capacity , ...ive of the world’s leading gene synthesis co...pply a common screening protocol to promote biosec...
(Date:11/18/2009)..., , DAVIS, Calif., Nov. 18 Mar...ery, development and commercialization of effectiv...products, announced that it has been named an IC20...es, oldest and largest national angel investing gr...rformance leading to rewarding results for all sta...
(Date:11/18/2009)..., CHAMPAIGN, Ill. Imagine a polka-dotted postage ... toxins simply by changing colors. , As reported...istry , Kenneth Suslick and his team at the Univer... for the general detection of toxic industrial che... and works by visualizing odors. This sensor arr...
(Date:11/18/2009)..., , Vernier,s experience in data analysis ... (TM) program kits and curricula provide s...on ,, BEAVERTON, Ore., Nov. 18 /PRNewswire/ -... educational science interfaces, sensors, and soft...al manufacturer and distributor of life science re...
Breaking Biology Technology:World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4Marrone Bio Innovations Named an IC20 Company 2Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education 2
...l/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ; TSX: A...,endocrine therapy and oncology, today reported th...y,s first efficacy trial of its Phase 3 program,in...us enlargement of the,prostate, with its flagship ...approximately 600 patients primarily in the United...
....,(SWX: ARPN) today announced that it will host a ...m CET. In this conference call, a leading expert w...he area of anti-infective,drugs as well as the out...gs Advisory Committee. During that meeting, the co... trial design for both mild/moderate and,moderate/...
...n Association for Cancer Research ...ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) announ...s,registrational bioequivalence clinical study of ...n Association for Cancer Research (AACR),Annual Me...kinetic,equivalence observed between an emulsion f...
Other Biology Technology:AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 4Arpida Announces Conference Call on 17 April 2Arpida Announces Conference Call on 17 April 3ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 2ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 3ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 4ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 5
(Date:11/20/2009)... - Bacteria possess an ingenious mechanism for pre... the cell. This is the new finding of a team of bi...e sciences research institute in Flanders, Belgium... scientists made this discovery by modifying the D... By means of this model organism, they have uncove...
(Date:11/20/2009)...Research Center (ERC) has been awarded a grant fro...ethods of recovering and reusing the heat that wou...ression process in a carbon capture system. The go... capture and sequestration, or storage (CCS), and ...emitted into the atmosphere by coal-fired power pl...
(Date:11/19/2009)...which cultivate fungus for food, have many remarka... list: the ant farmers, like their human counterpa...eir gardens grow. The finding, reported this week ...eviously unknown symbiosis between ants and bacter...have come to dominate the American tropics and sub...
Breaking Biology News(10 mins):Biologists discover bacterial defense mechanism against aggressive oxygen 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 3Like humans, ants use bacteria to make their gardens grow 2FDA Awards Three Grants Designed to Stimulate Development of Pediatric Medical Devices 57798 1FDA Awards Three Grants Designed to Stimulate Development of Pediatric Medical Devices 57798 2FDA Awards Three Grants Designed to Stimulate Development of Pediatric Medical Devices 57798 3GeoVax Labs Requests pre IND Meeting With FDA 14181 1GeoVax Labs Requests pre IND Meeting With FDA 14181 2GeoVax Labs Requests pre IND Meeting With FDA 14181 3Family Planning for the Worlds Poor 3A Who Will Pay 3F 57794 1Family Planning for the Worlds Poor 3A Who Will Pay 3F 57794 2
...iversity of Alaska Fairbanks neuroscientists study...resent their research findings at the 7th Conferen...ms in New York Aug. 19-22, 2008. , The scientists... at the UAF Institute of Arctic Biology, which is ...se goal is to expand and stimulate basic neuroscie...
... 2008 -- Elsevier, a leading global healthcare and...lists in The Elsevier Grand Challenge, a competiti...tools innovating how Life Sciences information is ...ts were chosen by a distinguished panel of judges ...nge of approaches involving semantics, visualizati...
...8, 2008 With oil prices skyrocketing, the search ...arch published this month in Agronomy Journal ex... Corn stover is made up of the leaves and stalks ...rvesting the edible corn grain. Corn stover could ...y 2030. , Scientists with the USDA-ARS Agroecosy...
Other Biology News:Stroke and SIDS in Alaska topics of neuroscience conference 2Elsevier announces 10 semi-finalists for the Elsevier Grand Challenge 2Elsevier announces 10 semi-finalists for the Elsevier Grand Challenge 3
Anti-p14ARF / p16Beta Ab-1 Polyclonal Antibody, Unconjugated from Lab Vision
Mouse Anti-Human MCAF-(MCP-1) Antibody, from Abazyme
Mouse Anti-Human Gastric Carcinoma Marker [BY-1] Monoclonal Antibody, Unconjugated, Clone 3H11 from Santa Cruz Biotechnology, Inc.
Goat Anti-LTBP-1 (E-20) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products: